Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
212 studies found for:    "Essential thrombocythemia"
Show Display Options
Rank Status Study
1 Completed Anagrelide Retard in Essential Thrombocythemia
Condition: Essential Thrombocythemia
Interventions: Drug: Anagrelide retard;   Drug: Thromboreductin
2 Completed
Has Results
French Observational Xagrid (FOX) Study In Adult Patients With Essential Thrombocythemia
Condition: Essential Thrombocythemia
Intervention:
3 Completed Anagrelide vs. Hydroxyurea - Efficacy and Tolerability Study in Patients With Essential Thrombocythaemia
Condition: Essential Thrombocythaemia
Interventions: Drug: Anagrelide;   Drug: Hydroxyurea
4 Completed
Has Results
The Pharmacokinetics of Anagrelide in Elderly and Young Patients With Essential Thrombocythaemia (ET)
Condition: Essential Thrombocythaemia
Intervention: Drug: anagrelide hydrochloride
5 Completed Anagrelide Retard vs. Placebo: Efficacy and Safety in "At-risk" Patients With Essential Thrombocythaemia
Condition: Essential Thrombocythaemia
Interventions: Drug: Anagrelide retard;   Drug: Placebo
6 Completed Pediatric Disease Registry in Essential Thrombocythaemia (ET)
Condition: Essential Thrombocythemia (ET)
Intervention:
7 Completed
Has Results
Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia
Condition: Essential Thrombocythemia (ET)
Intervention: Drug: SPD422 (anagrelide hydrochloride)
8 Not yet recruiting Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia
Conditions: MPN;   Essential Thrombocythemia
Interventions: Other: Aspirin therapy interruption;   Other: Usual treatment by aspirin 100 mg/d in the active comparator arm;   Other: No interruption of aspirin in the Observational arm;   Drug: Hydroxyurea treatment (HU)
9 Not yet recruiting Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)
Conditions: Myelofibrosis;   Essential Thrombocythemia
Intervention:
10 Unknown  A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia
Conditions: Polycythemia Vera;   Essential Thrombocythemia
Intervention: Drug: HDAC inhibitor (MK-0683)
11 Completed Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera
Conditions: Essential Thrombocythemia;   Polycythemia Vera
Intervention: Drug: Imetelstat
12 Terminated Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia
Conditions: Polycythemia Vera;   Essential Thrombocythemia
Intervention: Drug: Momelotinib
13 Completed Study of LY573636-sodium in Essential Thrombocythemia and Acute Myeloid Leukemia
Conditions: Acute Myeloid Leukemia;   Essential Thrombocythemia
Intervention: Drug: LY573636-sodium
14 Recruiting Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)
Conditions: High Risk Polycythemia Vera;   High Risk Essential Thrombocythemia
Interventions: Drug: PEGASYS;   Drug: Hydroxyurea;   Drug: Aspirin
15 Active, not recruiting
Has Results
Study to Determine the Safety and Efficacy of Ruxolitinib (INCB018424) in Patients With Polycythemia Vera or Essential Thrombocythemia
Conditions: Polycythemia Vera;   Essential Thrombocythemia
Intervention: Drug: Ruxolitinib
16 Recruiting Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)
Conditions: High Risk Polycythemia Vera;   High Risk Essential Thrombocythemia
Interventions: Drug: PEGASYS;   Drug: Aspirin
17 Recruiting Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia
Conditions: Polycythemia Vera;   Essential Thrombocythemia
Interventions: Drug: RG7388;   Drug: Pegasys
18 Recruiting The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia
Conditions: Polycythemia Vera (PV);   Essential Thrombocythemia (ET)
Interventions: Drug: Ruxolitinib;   Drug: BAT
19 Not yet recruiting The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line
Condition: Essential Thrombocythemia
Interventions: Drug: Anagrelide;   Drug: Ruxolitinib (JAKAVI®);   Drug: IFNα/ PegIFNα
20 Completed
Has Results
Exploratory Multi-centre Trial In Patients With ET Treated With XAGRID®
Condition: Essential Thrombocythaemia
Intervention: Drug: Anagrelide hydrochloride

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.